行情

RETA

RETA

Reata制药
NASDAQ

实时行情|Nasdaq Last Sale

213.67
+2.07
+0.98%
盘后: 197.00 -16.67 -7.80% 19:59 11/11 EST
开盘
209.17
昨收
211.60
最高
213.71
最低
207.88
成交量
49.69万
成交额
--
52周最高
215.10
52周最低
47.50
市值
64.33亿
市盈率(TTM)
-52.6917
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RETA 新闻

  • 沪指高开震荡 金价连续多日走低
  • 新浪财经.20分钟前
  • 腾讯音乐高管解读财报:付费会员营收增速超内容成本
  • 新浪科技.4小时前
  • Reata's bardoxolone successful in late-stage CKD study
  • seekingalpha.4小时前
  • 伊朗石油部长:新油田让伊朗原油储量仅增222亿桶
  • 中国新闻网.5小时前

更多

所属板块

生物技术和医学研究
-0.40%
制药与医学研究
-0.41%

热门股票

名称
价格
涨跌幅

RETA 简况

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
展开

Webull提供Reata Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。